Elevance Health’s 14.5x forward earnings valuation discounts a Medicaid margin trough, while Carelon growth, disciplined exits and 2027 earnings recovery offer a credible path to attractive long-term returns.
Overview
Elevance Health is a large U.S. managed-care company serving approximately 44.9 million medical members through Health Benefits and Carelon. Health Benefits spans commercial, Medicare, Medicaid, ACA and federal plans; Carelon adds pharmacy, specialty distribution and clinical services. Exclusive Blue Cross Blue Shield licenses in 14 states, scale, and commercial retention above 99% support a durable competitive position. Q2 2026 revenue was $49.8 billion, up 0.8% year over year and ahead of $48.6 billion consensus; adjusted diluted EPS of $7.45 beat the $6.21–$6.27 range by 18.85%. Management raised 2026 adjusted EPS guidance to at least $27.00 and operating cash flow guidance to at least $6.0 billion. Yet margins are under pressure: BER reached 89.7%, consolidated operating margin fell to 3.5%, and Medicaid is expected to run at roughly -1.75% in 2026. The investment case rests on **a cyclical Medicaid trough rather than a broken franchise**, with pricing and contract exits intended to reset returns. At $395.92, shares trade at 14.5x forward earnings and offer a 7.3% FCF yield. **Medicaid rate normalization and Carelon growth are the central catalysts**, alongside the 2027 target of at least 12% adjusted EPS growth.